Ellen Langille

Ellen Langille

Auto-generated profile, based on publicly available information

Ellen Langille

Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Systematically investigating the scores of genes mutated in cancer and discerning disease drivers from inconsequential bystanders is a prerequisite for precision medicine but remains challenging. Here, we developed a somatic CRISPR/Cas9 mutagenesis screen to study 215 recurrent “long-tail” breast cancer genes, which revealed epigenetic regulation as a major tumor-suppressive mechanism. We report that components of the BAP1 and COMPASS-like complexes, including KMT2C/D, KDM6A, BAP1, and ASXL1/2 (“EpiDrivers”), cooperate with PIK3CAH1047R to transform mouse and human breast epithelial cells. Mechanistically, we find that activation of PIK3CAH1047R and concomitant EpiDriver loss triggered an alveolar-like lineage conversion of basal mammary epithelial cells and accelerated formation of luminal-like tumors, suggesting a basal origin for luminal tumors. EpiDriver mutations are found in ∼39% of human breast cancers, and ∼50% of ductal carcinoma in situ express casein, suggesting that lineage infidelity and alveogenic mimicry may significantly contribute to early steps of breast cancer etiology. Significance: Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on epigenetic regulation. Loss of epigenetic regulators accelerated tumorigenesis and revealed lineage infidelity and aberrant expression of alveogenesis genes as potential early events in tumorigenesis. This article is highlighted in the In This Issue feature, p. 2711

4 April 2023
Verified
Other
Open access
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Systematically investigating the scores of genes mutated in cancer and discerning disease drivers from inconsequential bystanders is a prerequisite for precision medicine but remains challenging. Here, we developed a somatic CRISPR/Cas9 mutagenesis screen to study 215 recurrent “long-tail” breast cancer genes, which revealed epigenetic regulation as a major tumor-suppressive mechanism. We report that components of the BAP1 and COMPASS-like complexes, including KMT2C/D, KDM6A, BAP1, and ASXL1/2 (“EpiDrivers”), cooperate with PIK3CAH1047R to transform mouse and human breast epithelial cells. Mechanistically, we find that activation of PIK3CAH1047R and concomitant EpiDriver loss triggered an alveolar-like lineage conversion of basal mammary epithelial cells and accelerated formation of luminal-like tumors, suggesting a basal origin for luminal tumors. EpiDriver mutations are found in ∼39% of human breast cancers, and ∼50% of ductal carcinoma in situ express casein, suggesting that lineage infidelity and alveogenic mimicry may significantly contribute to early steps of breast cancer etiology.Significance:Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on epigenetic regulation. Loss of epigenetic regulators accelerated tumorigenesis and revealed lineage infidelity and aberrant expression of alveogenesis genes as potential early events in tumorigenesis.This article is highlighted in the In This Issue feature, p. 2711

4 April 2023
Verified
Other
Open access
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Supplementary Data from Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

4 April 2023
Verified
Other
Open access
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Supplementary Data from Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

4 April 2023
Verified
Other
Open access
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Supplementary Data from Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

4 April 2023
Verified
Other
Open access
ELEllen Langille
Ellen Langille
KAKhalid N. Al-Zahrani
Khalid N. Al-Zahrani
ZMZhibo Ma
Zhibo Ma
MLMinggao Liang
Minggao Liang
LULiis Uuskula-Reimand
Liis Uuskula-Reimand
DSDaniel Schramek
Daniel Schramek
Supplementary Data from Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer